Clinical trial
Combination Chemotherapy in Treating Women With Breast Cancer
NCT00003519 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003519 |
|---|---|
| Title | Combination Chemotherapy in Treating Women With Breast Cancer |
| Official title | Phase III Study of Adriamycin/Taxotere Versus Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH SWOG Cancer Research Network North Central Cancer Treatment Group Cancer and Leukemia Group B |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | cyclophosphamide, docetaxel, doxorubicin hydrochloride |
| Enrollment | 2,778 |
| Start date | Aug 20, 1998 |
| Primary completion | Jan 1, 2007 |
| First posted | Aug 26, 2004 |
| Last update posted | Jun 15, 2023 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: